Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) EPS (Basic): 2017-2024

Historic EPS (Basic) for Kiniksa Pharmaceuticals International (KNSA) over the last 8 years, with Dec 2024 value amounting to -$0.60.

  • Kiniksa Pharmaceuticals International's EPS (Basic) rose 238.89% to $0.25 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.49, marking a year-over-year increase of 476.92%. This contributed to the annual value of -$0.60 for FY2024, which is 400.00% down from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported EPS (Basic) of -$0.60 as of FY2024, which was down 400.00% from $0.20 recorded in FY2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's EPS (Basic) peaked at $2.64 during FY2022, and registered a low of -$2.61 during FY2020.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's median EPS (Basic) value was $0.20 (recorded in 2023), while the average stood at $0.75.
  • Its EPS (Basic) has fluctuated over the past 5 years, first skyrocketed by 214.78% in 2022, then tumbled by 400.00% in 2024.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's EPS (Basic) (Yearly) stood at -$2.61 in 2020, then rose by 11.88% to -$2.30 in 2021, then soared by 214.78% to $2.64 in 2022, then plummeted by 92.42% to $0.20 in 2023, then crashed by 400.00% to -$0.60 in 2024.